Sigrid enters exclusive global licensing and research collaboration to commercialize SiPore® in consumer-oriented oral health

Stockholm — January 21, 2026 — Sigrid Therapeutics (Sigrid) is a Swedish-based, science-driven consumer health company with a primary focus on metabolic health. Following the successful launch of its first two clinically proven products — Carb Fence , developed to support weight loss by reducing appetite and sugar cravings while promoting fat loss and preserving muscle mass , and Glucose Stabiliser , a dietary supplement to help regulate blood sugar after meals — Sigrid today announces that the company has entered into an exclusive global licensing and research collaboration with a leading multinational consumer health company to expand the SiPore® platform into consumer-facing oral health through a partner-led approach.

“While our primary focus is on the continued commercialization of Carb Fence and Glucose Stabiliser , this partnership enables us to realize additional value from the SiPore® platform in a capital-efficient and non-dilutive manner,” said Sana Alajmovic, Co-Founder and CEO of Sigrid . “The collaboration clearly demonstrates the potential of the SiPore® platform to address multiple major healthcare markets over time and represents a strong external validation following an extensive two-year scientific, technical and commercial due diligence conducted by our partner.”

The agreement covers the use of SiPore® in consumer-facing oral health formulations and establishes a framework for joint research and clinical evaluation, with the goal of enabling future commercialization following clinical validation. The collaboration represents an important milestone in the development of SiPore® as a platform technology with multiple application areas , in parallel with Sigrid's continued commercialization in metabolic health.

According to the agreement, Sigrid will receive:

• an advance payment,
• compensation linked to developmental and clinical milestones,
• additional sales-based milestone payments, and
• ongoing, long-term royalties on net sales.

The agreement is structured as a multi-year, royalty-bearing partnership , where Sigrid's compensation is directly linked to the commercial success of SiPore®-based products in global oral health markets. The arrangement enables capital-efficient and non-dilutive value creation , while reflecting a shared ambition to build sustainable value through scientific validation and global scale.

A differentiated platform for one of the world's largest everyday health markets

SiPore® is Sigrid's proprietary, non-systemic material technology platform based on precision engineered porous silica particles. In oral health, SiPore® works through a purely mechanical mechanism of action , where it binds and removes key proteins and enzymes involved in plaque and biofilm formation in the oral cavity. This enables an immediate and long-lasting first line of defense against plaque and caries, without systemic exposure.

Oral diseases — including dental caries and periodontal disease — are the world’s most common diseases, affecting an estimated 3.5 billion people globally . The global toothpaste market is valued at approximately USD 19 billion annually and is expected to grow to approximately USD 28 billion by 2034 , driven by an increased focus on prevention, premium products and science-based solutions for daily use.

Against this backdrop, consumer-focused oral health — especially the fast-growing mass premium segment — represents a strategically very attractive application area for the SiPore® platform, with the potential to support differentiated products on a global scale.

“Consumer-oriented oral health is a demanding category where safety, efficacy and daily usability are crucial,” says Damir Konakovic, Head of Oral Health at Sigrid . “The collaboration enables rigorous scientific validation of SiPore® in oral health, while benefiting from a partner with the capacity to translate science into products with global reach and scale.”